Annovis Bio, Inc. (NYSE: ANVS) shares were flat Thursday. The company, a Phase 3 clinical-stage biotechnology concern developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM, a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson’s study.
Annovis’ recently launched open-label study in PD patients (ANVS-25002) is currently enrolling participants across the 25 sites in the United States to test buntanetap for the duration of 36 months. As part of the initiative to advance management, monitoring, and data collection, the Company has entered into a partnership with NeuroRPM to introduce the first FDA-cleared AI-enabled medical device that allows to monitor the primary PD symptoms – bradykinesia, tremor, and dyskinesia. This information will serve as a digital biomarker, capturing real-time evidence of how disease symptoms change during the course of the study.
“We are excited to collaborate with NeuroRPM and believe that data-driven insights generated from its platform will complement our existing data collection and strengthen the evidence-based monitoring of disease progression throughout the trial,” commented Cheng Fang, Ph.D., Senior Vice President, Research and Development at Annovis.
ANVS closed Wednesday’s session at $2.45.
Related Stories
